

80 Rec'd CT/PTO 12DEC1997

U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NO.: 1581.0200000
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		DATE: December 12, 1997
INTERNATIONAL APPLICATION NO.: PCT/GB96/01409	INTERNATIONAL FILING DATE: 12 June 1996	U.S. APPLICATION NO. 08/981087 To be assigned
TITLE OF INVENTION: Type F Botulinum Toxin and Use Thereof		PRIORITY DATE CLAIMED: 12 June 1995
APPLICANTS FOR DO/EO/US: <u>ELMORE, Michael James</u> ; <u>MAUCHLINE, Margaret Lamble</u> ; <u>MINTON, Nigel Peter</u> ; <u>PASECHNIK, Vladimir Artymovich</u> ; <u>TITBALL, Richard William</u>		
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)): <ol style="list-style-type: none"> <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
ITEMS 11. TO 16. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:		
<ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: a.) Computer-readable diskette copy of sequence listing; b.) Statement Under 37 C.F.R. § 1.825(b); c.) Authorization to Treat A Reply As Incorporating An Extension of Time Under 37 C.F.R. § 1.136(a)(3) (in duplicate) 		

08/981087

-2-

08981087 052798
86/250 2807880

ATTORNEY'S DOCKET NO: 1581.0200000		
U.S. APPLICATION NO. (if known)	INTERNATIONAL APPLICATION	DATE:
To be assigned	PCT/GB96/01409	December 12, 1997

a. ☒ A check in the amount of \$1592.00 to cover the above fees is enclosed.
(This paper is filed in triplicate)

b. ☐ Please charge my Deposit Account No. 19-0036 in the amount of \$_____ to cover the above fees.
(A duplicate copy of this sheet is enclosed.)

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0036.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed to request that the application be restored to pending status.

Send All Correspondence To:

STERNE, KESSLER, GOLDSTEIN & FOX
1100 New York Ave., N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Robert W. Esmond Dec. 12, 1997
SIGNATURE DATE

Robert W. Esmond
NAME

32,893
REGISTRATION NUMBER

Rev. 7/93